Extending David Horrobin's membrane phospholipid theory of schizophrenia: Overactivity of cytosolic phospholipase A2 in the brain is caused by overdrive of coupled serotonergic 5HT2A/2C receptors in response to stress

Medical Hypotheses

Volumn 79, Issue 6, 2012, Pages 740-743

  Eggers, Arnold E ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; ICOSAPENTAENOIC ACID; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPASE A2; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CHRONIC STRESS; DISEASE ASSOCIATION; DORSAL RAPHE NUCLEUS; ENZYME ACTIVITY; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MIGRAINE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

BRAIN; CYTOSOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE LIPIDS; MODELS, THEORETICAL; PHOSPHOLIPASES A2; PHOSPHOLIPIDS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84869082871     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.08.016     Document Type: Article

References (33)

1. Horrobin D.F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977, 1:936-937.
2. Puri B.K., Easton T., Das I., Kidane L., Richardson A.J. The niacin skin flush test in schizophrenia: a replication study. Int J Clin Pract 2001, 55:368-370.
3. 2. Annu Rev Pharmacol Toxicol 1999, 39:175-189.
4. Horrobin D.F. The madness of Adam and Eve 2001, Transworld Publishers, London (UK), p. 157.
5. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998, 30:193-208.
6. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids 2003, 69:477-485.
7. 2 in neurodegenerative and neuropsychiatric conditions. Curr Med Chem 2010, 7:2746-2763.
8. 2 and of the release process in intact macrophages. Biochem J 1994, 301:455-458.
9. Rapoport S.I. In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 2001, 16:243-262.
10. Pettegrew J.W., Keshavan M.S., Panchalingam K., et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics. Arch Gen Psychiatry 1991, 48:563-568.
11. Fukuzako H. Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy. World J Biol Psychiatry 2001, 2:70-82.
12. Eggers A.E. Redrawing Papez' circuit: a theory about how acute stress becomes chronic and causes disease. Med Hypotheses 2007, 69:852-857.
13. Kohler C., Steinbusch H. Identification of serotonin and non-serotonin containing neurons of the mid-brain raphe projecting to the entorhinal area and the hippocampal formation. A combined immunohistochemical and fluorescent retrograde tracing study in the rat brain. Neuroscience 1982, 7:951-975.
14. Nauta W.J.H. Hippocampal projections and related neural pathways to the mid-brain in the cat. Brain 1958, 81:319-340.
15. Weiller C., May A., Limmroth V., et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658-660.
16. Moore R.Y., Halaris A.E. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975, 164:171-184.
17. Malbert J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic anti-depressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
18. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
19. Goff D.C., Sullivan L.M., McEnvoy J.P., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80:45-53.
20. Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T.M.S. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006, 51:382-386.
21. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007, 24:481-485.
22. Venkatasubramanian G., Chittiprol S., Neelakantachar N., et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naïve schizophrenia. Am J Psychiatry 2007, 164:1557-1560.
23. Van Nimwegen L.M.J., Storosum J.G., Blumer R.M.E., et al. Hepatic insulin resistance in antipsychotic naïve patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes. J Clin Endocrinol Metab 2008, 93:572-577.
24. Eggers A.E. Neurological theory of hypertension. Med Hypotheses 2003, 60:852-855.
25. Ross B.M., Hudson C., Ehrlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Arch Gen Psychiatry 1997, 54:487-494.
26. 2 in serum. Clin Chem 1985, 31:714-717.
27. Min J.-H., Jain M., Wilder C., et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in aqueous phase. Biochemistry 1999, 38:12935-12942.
28. Eggers A.E., Factor X.I.I. (Hageman factor) is a missing link between stress and hypercoagulability and plays an important role in the pathophysiology of ischemic stroke. Med Hypotheses 2006, 67:1065-1071.
29. Curran D.A., Hinterberger H., Lance J.W. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965, 88:997-1010.
30. D'Andrea G., Cananzi A., Toldo M., Cortelazzo S., Ferro-Milone F. Platelet behavior in classic migraine: responsiveness to small dose of aspirin. Thromb Haemost (Stuttgart) 1983, 49:153.
31. Hannington A., Jones R.J., Amess J.A.L., Wachowicz B. Migraine: a platelet disorder. Lancet 1981, 2:720-723.
32. Ailhaud G., Massiera F., Weill P., Legrand P., Alessandri J.-M., Guesnet P. Temporal changes in dietary fats: role of n-6 polyunsaturated fatty acids in excessive adipose tissue development and relationship to obesity. Prog Lipid Res 2006, 45:203-236.
33. Masseira F., Saint-Marc P., Seydoux J., et al. Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern?. J Lipid Res 2003, 44:271-279.